Moreover, niclosamide can eradicate CML LSCs through disrupting the interplay between p65 and FOXM1/β-catenin, and prolonged the survival of CML mice18. This evidence concerns the gene FOXM1 and chronic myelogenous leukemia, BCR-ABL1 positive.